Combining biomarkers to optimize patient treatment recommendations.

ABSTRACT: Markers that predict treatment effect have the potential to improve patient outcomes. For example, the OncotypeDX® RecurrenceScore® has some ability to predict the benefit of adjuvant chemotherapy over and above hormone therapy for the treatment of estrogen-receptor-positive breast cancer, facilitating the provision of chemotherapy to women most likely to benefit from it. Given that the score was originally developed for predicting outcome given hormone therapy alone, it is of interest to develop alternative combinations of the genes comprising the score that are optimized for treatment selection. However, most methodology for combining markers is useful when predicting outcome under a single treatment. We propose a method for combining markers for treatment selection which requires modeli

SUBMITTER: Kang C 

PROVIDER: S-EPMC4248022 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature